Bio-Thera And Pharmapark Add Cosentyx Rival To Russia-CIS Collaboration
Secukinumab Biosimilar Expands Deal That Already Includes Golimumab And Ustekinumab
China’s Bio-Thera Solutions and Russia’s Pharmapark have struck a deal to expand their existing biosimilars collaboration for Russia and the Commonwealth of Independent States with a further candidate: the Chinese firm’s BAT2306 proposed secukinumab biosimilar to Cosentyx.
